Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1997

View Archived Issues

New CNS agents with 5-HT2C-antagonist activity from Fujisawa

Allergan continues research into retinoids and retinoid-like compounds

Neurocrine Bioscience's CRF antagonists for stress-related disorders

Japanese researchers describe compounds for lipoprotein disorders

Anti-HIV agents from Shionogi

NOS inhibitors described by JT

Sankyo prepares prostaglandin derivatives for ulcers

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Novel series with anti-HIV and antimalarial activity

Aronex describes anti-HCMV compound

Gilead selects GS-930 prodrug for further evaluation

PMPA prodrug selected as clinical candidate

Anti-HIV agent that targets NCp7 zing fingers

British scientists describe novel therapeutic approach to HIV

Ganciclovir prodrug shows potential for treatment of CMV retinitis

Preliminary efficacy and safety data for an HIV therapeutic vaccine

Memorial Sloan-Kettering and Sequana form cancer joint venture

Inhale/Lilly collaborate on pulmonary delivery of osteoporosis Rx

Structural Bioinformatics and CyberChemics collaborate on viral protease inhibitors

Successful completion of phase I trial of aerosolized osteoporosis product

Preclinical results indicate potential of new approach to treatment of solid tumors

Companies aim for development of rapid one-step HIV urine test

Arthritis test enters clinic

Gene causing glaucoma located and cloned

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...